Skip Navigation

Cardiovascular Research 2003 57(2):523-534; doi:10.1016/S0008-6363(02)00697-1
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Martire, A.
Right arrow Articles by Schaper, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martire, A.
Right arrow Articles by Schaper, W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice mimics ischemic preconditioning through SAPK/JNK1/2 activation

Alessandra Martirea,*, Borja Fernandeza, Alexandra Buehlera, Claudia Strohma, Jutta Schapera, René Zimmermannb, Pappachan E Kolattukudyc and Wolfgang Schapera

aDepartment of Experimental Cardiology, Max-Planck-Institute, Benekestrasse 2, D-61231 Bad Nauheim, Germany
bKerckhoff-Clinic, Bad Nauheim, Germany
cNeurobiotechnology Center, The Ohio State University, Columbus, OH, USA

* Corresponding author. Tel.: +49-6032-705-402; fax: +49-6032-705-419. a.martire{at}kerckhoff.mpg.de

Objective and methods: Although a beneficial association between innate immunity and ischemic preconditioning has recently been proposed, the mechanisms responsible for this link are poorly understood. To test the hypothesis that pro-inflammatory cytokines have a beneficial role in the activation of the cell survival pathway mediated by ischemic preconditioning, we have studied transgenic mice with cardiac myocyte specific overexpression of murine monocyte chemoattractant protein-1 (MCP-1). The resistance to ischemia was studied by performing 45-min (with or without injection of the SAPK/JNKs inhibitor D-JNKI1) and 3-day left coronary artery occlusions as well as 45-min left coronary artery occlusion followed by 3 days of reperfusion. In addition, quantitative Western blot analyses for TNF-{alpha}, and SAPK/JNK1/2, ERK1/2 and p38 activity were performed. Results: Infarct size, expressed in percent of either the risk area or the left ventricle, was reduced in transgenic mice when compared with control after both, 45-min (14.7±2.6% vs. 52.0±2.4%; P<0.05) and 45-min occlusion followed by 3 days of reperfusion (23.2±1.8% vs. 30.0±1.8%; P<0.05) but it was not significantly different for 3-day occlusion. Western blot analyses showed significantly increased levels of TNF-{alpha} (1.8-fold) and phosphorylated-SAPK/JNK1/2 (1.5-fold) in transgenic hearts. Phosphorylated-ERK1/2, and phosphorylated-p38 levels were unchanged. Immunohistochemistry revealed that in transgenic mice monocytes/macrophages, lymphocytes, and fibroblasts are the source of TNF-{alpha}, whereas myocytes have increased phosphorylated-SAPK/JNK1/2 levels. In addition, injection of the SAPK/JNKs inhibitor D-JNKI1 partially abrogated the cardioprotective effect observed in untreated transgenic mice. Conclusion: Overexpression of MCP-1 by cardiomyocytes causes chronic infiltration and activation of leukocytes, resulting in elevated TNF-{alpha} secretion and SAPK/JNK1/2 activation. The activation of this pathway is in part responsible for the preconditioning effect of MCP-1 overexpression. These results show a possible beneficial link between innate immunity and ischemic preconditioning through MAP-kinase activation.

KEYWORDS Cytokines; Ischemia; Leukocytes; Preconditioning; Signal transduction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Circ. Res.Home page
W. Schaper
The Renaissance of Vascular Endothelial Growth Factor, Part B
Circ. Res., October 24, 2008; 103(9): 903 - 904.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
H. Morimoto, M. Hirose, M. Takahashi, M. Kawaguchi, H. Ise, P. E. Kolattukudy, M. Yamada, and U. Ikeda
MCP-1 induces cardioprotection against ischaemia/reperfusion injury: role of reactive oxygen species
Cardiovasc Res, June 1, 2008; 78(3): 554 - 562.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
C Stumpf, C Lehner, D Raaz, A Yilmaz, T Anger, W G Daniel, and C D Garlichs
Platelets contribute to enhanced MCP-1 levels in patients with chronic heart failure
Heart, January 1, 2008; 94(1): 65 - 69.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Blum, R. Asaf, J. Guetta, R. Miller-Lotan, R. Asleh, R. Kremer, N. S. Levy, F. G. Berger, D. Aronson, X. Fu, et al.
Haptoglobin Genotype Determines Myocardial Infarct Size in Diabetic Mice
J. Am. Coll. Cardiol., January 2, 2007; 49(1): 82 - 87.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. Morimoto, M. Takahashi, A. Izawa, H. Ise, M. Hongo, P. E. Kolattukudy, and U. Ikeda
Cardiac Overexpression of Monocyte Chemoattractant Protein-1 in Transgenic Mice Prevents Cardiac Dysfunction and Remodeling After Myocardial Infarction
Circ. Res., October 13, 2006; 99(8): 891 - 899.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
L. Zhou, A. Azfer, J. Niu, S. Graham, M. Choudhury, F. M. Adamski, C. Younce, P. F. Binkley, and P. E. Kolattukudy
Monocyte Chemoattractant Protein-1 Induces a Novel Transcription Factor That Causes Cardiac Myocyte Apoptosis and Ventricular Dysfunction
Circ. Res., May 12, 2006; 98(9): 1177 - 1185.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.